Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones

(TheNewswire)

2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” ,FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, today announcedthat the Company has appointed Rohit Babbar, CPA as Chief FinancialOfficer ( “CFO” ) of the Company, replacing James B. Murphy, CPA asFractional CFO.

Rohit Babbar is Certified Public Accountant withfourteen years of experience leading accounting operations andfinancial strategy across fast-growing private and publicly listedsmall to mid-sized companies in Canada and the US. He is a Director atBrio Financial Group ( “Brio” ), a financial consulting firm thatprovides outsourced CFO services, financial planning and analysis, andstrategic advisory support to emerging growth companies. Over thecourse of his career, Mr. Babbar has delivered impact across strategicgrowth and operational efficiency, leading transformative initiativessuch as a USD 50 million private equity deal that helped drive atenfold revenue increase from USD 20 million to USD 200 million. Mr.Babar will be supported by an experienced team of professionals fromBrio specializing in accounting and finance, capital raising andadministrative operations, as Helix enters a new phase of growth thatincludes plans to relocate to the US, pursue a NASDAQ listing, andclose a substantial equity financing to support upcoming clinicalstudies.

“Rohit’s leadership and Brio’s support willprovide the bandwidth we need as we prepare to execute on theCompany’s upcoming strategic milestones—particularly as we gear upfor our interactions with the FDA—ensuring our financial operationsare aligned and fully resourced to support clinical execution,” said Dr. Thomas Mehrling, MD, PhD,CEO of Helix BioPharma.

Rohit Babbar, CPA, CFO of Helix added: “I’m excited to join Helix at such apivotal stage in its evolution. The Company’s scientific foundationand strategic direction present a compelling opportunity to buildlong-term value. I look forward to working closely with the team tohelp drive its financial strategy and support its upcomingmilestones.”

About Brio Financial Group

Brio Financial Group is a financial and managementconsulting firm based in Somerville, New Jersey, specializing inoutsourced financial leadership and reporting support for small tomid-sized public and private companies. With a team experienced acrossdomestic and international markets, Brio has supported clients listedon multiple stock exchanges and is frequently referred by leadingaudit firms—including sole practitioners and Big Four firms alike.Brio’s services span complex financial analysis, accounting formergers and acquisitions, valuation of financial instruments, and thedevelopment of robust financial reporting frameworks. In addition toensuring compliance and managing financial reporting and taxation, thefirm provides strategic financial management solutions, includingbudgeting, modeling, capital procurement, and accounting systemdesign. Brio is known for helping emerging growth companies navigatefinancial complexity with clarity and confidence.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit : https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, LR 09 andGEMCEDA. Forward-looking statements can further be identified by theuse of forward-looking terminology such as “ongoing”,“estimates”, “expects”, or the negative thereof or any othervariations thereon or comparable terminology referring to futureevents or results, or that events or conditions “will”, “may”,“could”, or “should” occur or be achieved, or comparableterminology referring to future events or results.

Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that the Company'sassumptions on which its forward-looking statements are based may notbe accurate; the ability of the Company to capitalize on the potentialbenefits of the transactions; and the risk factors disclosed in theCompany's periodic reports publicly filed and available on its SEDAR+profile at www.sedarplus.ca . No assurance can be given that any of the events anticipated bythe forward-looking statements will transpire or occur. There is noassurance that the proposed transactions will be completed inaccordance with its terms or at all. The forward-looking statementscontained in this news release are made as of the date of thisannouncement and the Company does not assume any obligation to updateany forward-looking statement or information should those beliefs,assumptions, opinions or expectations, or other circumstances change,except as required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.